Share chart PolyPid Ltd.
Extended chart
Simple chart
About
PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
IPO date |
2020-06-26 |
ISIN |
IL0011326795 |
Industry |
Biotechnology |
Sector |
Health Care |
Валюта |
usd |
Валюта отчета |
usd |
Сайт |
https://www.polypid.com
|
Цена ао |
4.84 |
Change price per day: |
+1.4% (2.85) |
Change price per week: |
-10.25% (3.22) |
Change price per month: |
-16.35% (3.455) |
Change price per 3 month: |
-20.17% (3.62) |
Change price per half year: |
-27.75% (4) |
Change price per year: |
-23.95% (3.8) |
Change price per 3 year: |
-49.48% (5.72) |
Change price per 5 year: |
0% (2.89) |
Change price per 10 year: |
0% (2.89) |
Change price per year to date: |
-16.35% (3.455) |
|
Underestimation
Title |
Value |
Grade |
P/S |
0 |
0 |
P/BV |
-2.42 |
0 |
P/E |
0 |
0 |
EV/EBITDA |
-0.5341 |
0 |
Total: |
|
2.5 |
|
Efficiency
Title |
Value |
Grade |
ROA, % |
-155.25 |
0 |
ROE, % |
1138.6 |
10 |
Total: |
|
3.33 |
|
|
Dividends
Title |
Value |
Grade |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0 |
|
Debt
Title |
Value |
Grade |
Debt/EBITDA |
-0.519 |
10 |
Total: |
|
9.8 |
|
Growth impulse
Title |
Value |
Grade |
Yield Revenue, % |
0 |
0 |
Yield Ebitda, % |
-30.61 |
0 |
Yield EPS, % |
-4857.39 |
0 |
Total: |
|
0 |
|
Head |
Job title |
Payment |
Year of birth |
Ms. Dikla Czaczkes Akselbrad |
CEO & Director |
347.88k |
1973 (52 years) |
Ms. Dalit Hazan |
Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs |
272.38k |
1971 (54 years) |
Mr. Ori Warshavsky |
Chief Operating Officer - US |
340.89k |
1978 (47 years) |
Mr. Jonny Missulawin |
Chief Financial Officer |
186.96k |
1987 (38 years) |
Ms. Maria Rubin |
Vice President of Operations |
N/A |
|
Mr. Tal Vilnai |
General Counsel & Corporate Secretary |
N/A |
|
Ms. Rivi Lev-ari |
Vice President of Human Resource |
N/A |
|
Dr. Jean-Marc Hagai Pharm.D. |
Chief Commercial Officer |
N/A |
|